Patent US4935372A successfully refreshed from Google Patents.
US4935372A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Art nucleotide segments, vectors, cell lines methods of preparation and use
Assignee: Dana Farber Cancer Institute Inc
•
Filing: 1986-05-20
•
Granted: 1990-06-19
•
Expires: 2006-05-20
Abstract
Abstract A gene and gene product that regulates the expression of the capsidal envelope genes of HTLV-III/LAV and that can be used to regulate the expression of heterologous (non-viral) genes as well is disclosed. This art gene consists of two exons and can be used in creating nucleotide segments, vectors and cell lines. A new method for screening for compounds that inhibit the replication of HTLV-III is also described and comprises: (1) transfecting a T-cell line with the HTLV-III art and env genes; (2) thereafter, adding a preselected compound to the transformed cell line in increasing concentrations; and (3) determining whether the compound effects the art function without being toxic to the cell. An additional parameter to use in diagnosis of AIDS disease is also described. The use of the art gene and gene product in AIDS therapy is also disclosed.
Inventors
- 👤 Wei C. Goh
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-29 07:24
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; C12; C12N; C12N15/00; C12N15/09; C12N15/63; C12N15/79; C12N15/85; C12N2740/00; C12N2740/00011; C12N2740/10011; C12N2740/14011; C12N2740/14022; C12N2740/16011; C12N2740/16311; C12N2740/16322; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/221
Claims Analysis
Total Claims: 26
Claim 1
Independent Claim
50 words
A DNA segment comprising a nucleotide sequence coding for production of the HTLV-III art protein but not containing a sufficient number of nucleotide sequences to code for a functional HTLV-III protein selected from the group of HTLV-III proteins consisting of 3' orf protein, gag protein, env protein and tat protein.
Claim 2
Dependent Claim
50 words
A DNA segment comprising a nucleotide sequence coding for production of the HTLV-III art protein but not containing a sufficient number of nucleotide sequences to code for a functional HTLV-III protein selected from the group of HTLV-III proteins consisting of 3' orf protein, gag protein, env protein and tat protein.
Claim 3
Dependent Claim
47 words
The DNA segment of claim 1 comprising a sufficient number of nucleotides shown in FIG. 1B corresponding to a first nucleotide sequence between about 5500 to about 5625 and a second nucleotide sequence between about 7956 and about 8227 to express a poplypeptide having a trans-acting function.
Claim 4
Dependent Claim
24 words
A DNA segment according to claim 1, and having the nucleotide sequences 5550 to 5625 and 7956 to 8227 as shown in FIG. 1B.
Claim 5
Dependent Claim
22 words
The DNA segment of claim 1, which does not contain a sufficient number of nucleotide sequences to code for functional tat protein.
Claim 6
Dependent Claim
14 words
The DNA segment of claim 4 which does not contain the tat initiation codon.
Claim 7
Dependent Claim
49 words
A vector comprised of non-HTLV-III sequences and the coding sequences of the HTLV-III art gene but not a sufficient portion of the coding sequences of at least one of the HTLV-III genes selected from the group consisting of 3'orf, gag, env and tat to express a functional gene product.
Claim 8
Dependent Claim
49 words
A vector comprised of non-HTLV-III sequences and the coding sequences of the HTLV-III art gene but not a sufficient portion of the coding sequences of at least one of the HTLV-III genes selected from the group consisting of 3'orf, gag, env and tat to express a functional gene product.
Claim 9
Dependent Claim
78 words
A vector containing a sufficient amount of the HTLV-III art gene, to be able to express an HTLV-III art gene product that exhibits trans-activating activity, a sufficient amount of the HTLV-III LTR responsive to the HTLV-III art gene product for trans-activation and an enhancer upstream of the HTLV-III responsive segment but not a sufficient amount of at least one gene selected from the group consisting of 3' orf, gag, env, and tat to express a functional gene product.
Claim 10
Dependent Claim
78 words
A vector containing a sufficient amount of the HTLV-III art gene, to be able to express an HTLV-III art gene product that exhibits trans-activating activity, a sufficient amount of the HTLV-III LTR responsive to the HTLV-III art gene product for trans-activation and an enhancer upstream of the HTLV-III responsive segment but not a sufficient amount of at least one gene selected from the group consisting of 3' orf, gag, env, and tat to express a functional gene product.
Claim 11
Dependent Claim
18 words
The vector of claim 7 wherein the sufficient amount of the HTLV-III LTR is the HTLV-III TAR element.
Claim 12
Dependent Claim
27 words
The vector of claim 6, which does not contain a sufficient portion of the coding sequences of the tat gene to express a functional tat gene product.
Claim 13
Dependent Claim
23 words
The vector of claim 7, which does not contain a sufficient amount of the tat gene to express a functional tat gene product.
Claim 14
Dependent Claim
13 words
The vector of claim 9 which does not contain the tat initiation codon.
Claim 15
Dependent Claim
13 words
The vector of claim 10, which does not contain the tat initiation codon.
Claim 16
Dependent Claim
38 words
A stable cell line containing and expressing the HTLV-III art gene but not containing a sufficient number of nucleotides to express a HTLV-III protein-selected from the group consisting of 3'orf protein, gap protein, env protein and tat protein.
Claim 17
Dependent Claim
38 words
A stable cell line containing and expressing the HTLV-III art gene but not containing a sufficient number of nucleotides to express a HTLV-III protein-selected from the group consisting of 3'orf protein, gap protein, env protein and tat protein.
Claim 18
Dependent Claim
14 words
The stable cell line of claim 13, which does not express the tat protein.
Claim 19
Dependent Claim
15 words
The stable cell line of claim 14, which does not contain the tat initiation codon.
Claim 20
Dependent Claim
15 words
The art cell line of claim 13 where the cell is a Raji cell line.
Claim 21
Dependent Claim
14 words
The art cell of claim 13 where the cell is a HeLa cell line.
Claim 22
Dependent Claim
16 words
The art cell line of claim 13 where the cell is a NIH 3T3 cell line.
Claim 23
Dependent Claim
15 words
The art cell line of claim 13 where the cell is a Jurkat cell line.
Claim 24
Dependent Claim
15 words
The art cell line of claim 13 where the cell is a human T-cell line.
Claim 25
Dependent Claim
15 words
The art cell line of claim 13 where the cell is a human B-cell line.
Claim 26
Dependent Claim
15 words
The art cell line of claim 13 where the cell is a CHO cell line.
References Cited (Backward Citations)
US4752565A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-06-18 | 1993-12-18 | 1994-06-19 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-06-18 | 1997-12-18 | 1998-06-19 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-06-18 | 2001-12-18 | 2002-06-19 | $7700.00 | Window Closed / Lapsed |